Literature DB >> 17270554

Treatment of lymphangioma in children: our experience of 128 cases.

Tadaharu Okazaki1, Saori Iwatani, Toshihiro Yanai, Hiroyuki Kobayashi, Yoshifumi Kato, Takashi Marusasa, Geoffrey J Lane, Atsuyuki Yamataka.   

Abstract

PURPOSE: The aim of this study is to investigate the optimal treatment for lymphangioma in children by analyzing the effectiveness and complications of treatment modalities.
METHODS: We reviewed 128 patients with lymphangioma treated at our institution between 1979 and 2005. Periods of treatment were divided arbitrarily into 2 groups: period I, from 1979 to 1988 (n = 53); and period II, from 1989 to 2005 (n = 75). According to radiological appearance, patients were grouped into 4 types: single cystic (SI; n = 23), macrocystic (MA; n = 11), microcystic (MI; n = 69), and cavernous (CA; n = 25).
RESULTS: Sclerotherapy as primary treatment was performed in only 2 patients (3.8%) in period I using bleomycin but increased significantly in period II to 48 patients (64.0%) using OK-432 (P < .01). Nevertheless, primary surgical excision (69/78 patients, 88.5%) was significantly more successful than sclerotherapy (32/50, 64.0%) (P < .01). The following are the locations and types of lesions: head/neck (n = 69; SI, 11; MA, 5; MI, 42; CA, 11), trunk (n = 34; SI, 6; MA, 6; MI, 15; CA, 7), and extremities/other (n = 25; SI, 6; MI, 12; CA, 7). The effectiveness of sclerotherapy in SI, MA, MI, and CA types was 90.9%, 100%, 68.0%, and 10.0%, respectively. Seventeen patients (SI, 1; MI, 8; CA, 8) who received primary sclerotherapy required surgical excision with good outcome. Complications after primary surgical excision were more serious compared with sclerotherapy.
CONCLUSION: Sclerotherapy with OK-432 was not as effective as reported in the literature. We recommend OK-432 injection therapy alone for SI and MA types and surgical excision after pretreatment with OK-432 for MI and CA types.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270554     DOI: 10.1016/j.jpedsurg.2006.10.012

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  35 in total

1.  Treatment of lymphangioma of the face with intralesional bleomycin: case discussion and literature review.

Authors:  Sertac Yetiser; Kutlay Karaman
Journal:  J Maxillofac Oral Surg       Date:  2011-04-20

2.  Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy.

Authors:  Arvind Shergill; Philip John; Joao G Amaral
Journal:  Pediatr Radiol       Date:  2012-05-31

3.  Giant cystic lymphangioma originating from the cardia of the stomach: A case report.

Authors:  Geng Chen; Mingqing Liu; Tayyab Hamid Malik; Shouying Li; Ying Tang; Hong Xu
Journal:  Exp Ther Med       Date:  2016-02-19       Impact factor: 2.447

4.  Embolization in the head and neck.

Authors:  Daniel Cooke; Basavaraj Ghodke; Sabareesh Kumar Natarajan; Danial Hallam
Journal:  Semin Intervent Radiol       Date:  2008-09       Impact factor: 1.513

5.  A giant lymphangioma of the body wall in a child: a heavy companion.

Authors:  Harshjeet Singh Bal; Susan Jehangir; Jujju Jacob Kurian
Journal:  BMJ Case Rep       Date:  2014-11-26

6.  Vesicular and verrucous hemorrhagic plaque in a young adolescent girl.

Authors:  Noor Al-Mozan; Gillian Heinecke; David Pompei; Jason Emer
Journal:  J Clin Aesthet Dermatol       Date:  2012-11

7.  OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome.

Authors:  Dong Wook Kim
Journal:  Pediatr Radiol       Date:  2014-02-26

8.  Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant.

Authors:  Maolei Xu; Yun Xing; Ling Zhou; Xue Yang; Wenjun Yao; Wen Xiao; Chiyu Ge; Yanjun Ma; Jie Yang; Jie Wu; Rongyue Cao; Taiming Li; Jingjing Liu
Journal:  Tumour Biol       Date:  2013-03-01

Review 9.  Update on hemangiomas and vascular malformations of the head and neck.

Authors:  Behfar Eivazi; Mircia Ardelean; Wolfgang Bäumler; Hans-Peter Berlien; Hansjörg Cremer; Ravindhra Elluru; Peter Koltai; Jan Olofsson; Gresham Richter; Bernhard Schick; Jochen A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

10.  Targeting lymphatic vessel functions through tyrosine kinases.

Authors:  Steven P Williams; Tara Karnezis; Marc G Achen; Steven A Stacker
Journal:  J Angiogenes Res       Date:  2010-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.